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ABSTRACT
Objectives: To investigate the pathophysiological
pathways leading to symptoms elicitation in multiple
chemical sensitivity (MCS) by comparing gene
expression in MCS participants and healthy controls
before and after a chemical exposure optimised to
cause symptoms among MCS participants.
The first hypothesis was that unexposed and
symptom-free MCS participants have similar gene
expression patterns to controls and a second
hypothesis that MCS participants can be separated
from controls based on differential gene expression
upon a controlled n-butanol exposure.
Design: Participants were exposed to 3.7 ppm
n-butanol while seated in a windowed exposure
chamber for 60 min. A total of 26 genes involved in
biochemical pathways found in the literature have been
proposed to play a role in the pathogenesis of MCS
and other functional somatic syndromes were selected.
Expression levels were compared between MCS and
controls before, within 15 min after being exposed to
and 4 hours after the exposure.
Settings: Participants suffering from MCS and healthy
controls were recruited through advertisement at public
places and in a local newspaper.
Participants: 36 participants who considered
themselves sensitive were prescreened for eligibility.
18 sensitive persons fulfilling the criteria for MCS were
enrolled together with 18 healthy controls.
Outcome measures: 17 genes showed sufficient
transcriptional level for analysis. Group comparisons
were conducted for each gene at the 3 times points
and for the computed area under the curve (AUC)
expression levels.
Results: MCS participants and controls displayed
similar gene expression levels both at baseline and
after the exposure and the computed AUC values were
likewise comparable between the 2 groups. The
intragroup variation in expression levels among MCS
participants was noticeably greater than the controls.
Conclusions: MCS participants and controls have
similar gene expression levels at baseline and it was
not possible to separate MCS participants from
controls based on gene expression measured after the
exposure.
INTRODUCTION
Chemical intolerance (CI) towards everyday
chemicals, such as fragranced products,
freshly printed papers or magazines, car
exhausts or new furniture is reported by a
substantial proportion of the general adult
population.1–5 A subgroup with CI reports
severely debilitating symptoms when exposed
to these airborne chemicals, often with nega-
tive impact on social and occupational life
and reduction in overall life quality.6–8 This
Strengths and limitations of this study
▪ This is the first study comparing gene expression
levels between participants with multiple chem-
ical sensitivity (MCS) and healthy controls before
and upon a chemical exposure session optimised
to trigger MCS characteristic symptom among
MCS participants.
▪ The exposure sessions ability to segregate MCS
participants from controls based on a phenotypic
response had previously been verified, including
increased symptoms levels, higher than normal
pulse rate and lower than normal pulse rate vari-
ability associated with the MCS group.
▪ Genes included in the study were preselected
based on their possible role in regulation of
characteristic symptoms of MCS, their involve-
ment in the physiological response observed
during the exposure session, or because of their
involvement in the proposed biological explana-
tory models of MCS.
▪ The limited number of study participants enrolled
does represent a weakness of the study and any
follow-up studies would benefit from having a
larger and more representative study populations.
▪ MCS participants represent a fairly heteroge-
neous population in terms of which odours that
cause symptom elicitation as well as the symp-
toms reported, and this intragroup variability
observed among MCS participants only constitu-
tes a statistical challenge for the group compari-
sons performed.
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severe form of CI is commonly referred to as multiple
chemical sensitivity (MCS).8–11 The prevalence of MCS
in the adult population has been reported in the ranges
from 0.5% to 6.3%, with a higher prevalence in women
compared with men.1–4 12–14 Symptoms from the central
nervous system (CNS), for example, headache, dizziness
or fatigue, are considered mandatory in most deﬁnitions
of MCS,10 often in combination with one or several non-
speciﬁc symptoms from other organ systems including
the mucosa/respiratory tract, musculoskeletal system and
the gastrointestinal tract.3 10 15 How to deﬁne and isolate
cases with MCS is an ongoing challenge both clinically
and in terms of research and variable case deﬁnitions
have been proposed and applied across the scientiﬁc lit-
erature,8 most prominently being the 1999 US Consensus
Criteria,9 later extended with clariﬁcations suggested by
Lacour and colleagues in 2005.9 10 However, considering
the complexity of MCS it may not even be possible to
compose a single deﬁnition that is sensitive and speciﬁc
enough to cover both diagnostics and various research
and epidemiological purposes.8 16 17
Why some individuals develop MCS also remains dis-
puted and the nature as well as the scale of symptoms
experienced cannot be explained by traditional toxico-
logical dose–response relationships.15 Multiple causative
modes of action have been suggested to explain the
disease mechanisms behind MCS, encompassing both
physiological and psychological processes.11 18–22
However, although some clinical evidence in support of
several suggested pathophysiological models is available,
no conclusions can be drawn based on current knowl-
edge.8 23 Consequently, participants with MCS are
offered insufﬁcient healthcare solutions and experience
being met with doubt or limited understanding of their
condition by healthcare professionals, the social welfare
system and the society in general.8 24–26 It is therefore
essential that a deeper knowledge about the pathogenic
pathways leading to symptoms elicitation in participants
with MCS is being generated. Gene expression proﬁling
is a recognised and reliable technique that can be used
to quantitatively track functional gene expression pat-
terns under varying environmental and experimental
conditions, thereby providing novel information about
the biochemical pathways activation at a speciﬁc time
point (TP). It has yet to be applied in studies of MCS,
but the technique has recently shown promising results
in the detection of potential biomarkers in chronic
fatigue syndrome,27–29 a disorder that share many simi-
larities with MCS.
In the present study, we used a similar approach,27–29
to investigate whether exposure to a symptom-eliciting
chemical (n-butanol) could provoke changes in tran-
scription levels of selected genes in leucocytes from
MCS participantscompared with healthy controls, indica-
tive of differential transcriptional regulation.
The ability to segregate MCS participantsfrom controls
based on the phenotypic responses to the exposure
session have previously been described,30 and we have
also veriﬁed in the same individuals that localised upper
airway inﬂammation is not a part of the pathology, sug-
gesting that symptom elicitation in MCS has to be driven
by systemic mechanisms.31 We expected this to be mani-
fested as changes in gene transcription rates, and that
differences in this response could indicate pathways
involved in the MSC phenotype. As genetic studies in
MCS so far have been inconclusive,8 and this being the
ﬁrst gene expression proﬁling study focusing on MCS, it
was conducted as an explorative study. We chose to
measure gene expression in leucocytes isolated from
peripheral blood samples, because peripheral leucocytes
are easily available, they have already been used to iden-
tify gene expressional changes in patients with chronic
fatigue syndrome upon symptom elicitation,27–29 and
because numerous studies of MCS and other functional
somatic syndromes (FSS) have found indications of
inﬂammatory abnormalities in these conditions.8 24 32–34
Based on available knowledge in FSS in general and
MCS in particular, 26 genes were selected. The genes
belonged to the following regulatory categories: genes
involved in immune regulation, the physiological stress
response, sensory detection and enzymes of the
sphingosine-1-phosphate pathway.
The following two hypotheses were tested: (1) unex-
posed MCS participants and healthy controls will show
similar expression of the include genes of interest, and
(2) upon a controlled n-butanol exposure, MCS partici-
pants and healthy controls can be distinguished on
group levels based on differential gene expression
patterns.
MATERIAL AND METHODS
Study population
Participants suffering from MCS and healthy controls
were recruited through advertisement at public places
and in a local newspaper covering the Västerbotten
County in Sweden. Exclusion criteria were smoking, preg-
nancy, current breast feeding and a diagnosis of ﬁbro-
myalgia, chronic fatigue syndrome or irritable bowel
syndrome given by a physician. An additional exclusion
criterion included anosmia, and all participants were
prior to the exposure screened for this condition using a
0.44% v/v (336 ppm) concentration of n-butanol (99%,
Merck) of the Connecticut Chemosensory Clinical
Research Center Threshold Test.35
A total of 36 participants who considered themselves
especially sensitive were contacted by phone and pre-
screened for eligibility using the US Consensus Criteria
for MCS9 and the revisions suggested by Lacour et al,10
which were operationalised as follows: (1) symptoms for
at least 6 months; (2) symptoms occur in response to
exposure to low levels of chemicals that do not induce
symptoms in other participants who are exposed to the
same levels; (3) symptoms occur when exposed, and
lessen or resolve when the symptom-triggering exposure
is removed; (4) symptoms are elicited by at least two
2 Dantoft TM, et al. BMJ Open 2017;7:e013879. doi:10.1136/bmjopen-2016-013879
Open Access
group.bmj.com on March 27, 2017 - Published by http://bmjopen.bmj.com/Downloaded from 
unrelated chemical substances; (5) presence of at least
one symptom from the CNS (eg, headache, fatigue, diz-
ziness, memory problems, concentration difﬁculties or
tiredness) and one symptom from another organ system;
(6) symptoms that cause signiﬁcant impairment in daily
life, either in social, recreational, occupational, educa-
tional or economic situations (conﬁrmed by the score
on the Chemical Sensitivity Scale,36 table 2). A total of
18 participants (16 women, 2 men) fulﬁlled the MCS
criteria and were included in the study.
Eighteen participants (14 women, 4 men) were
recruited as age-matched and sex-matched healthy con-
trols. The controls did not fulﬁl any of the study criteria
for MCS, and reported no avoidance behaviour, annoy-
ance or symptoms attributed to low-level chemical expos-
ure. None of the participants in the control group
shared housing with an MCS affected individual or had
any close relative, that is, parent, grandparent, sibling or
child with MCS.
Exposure chamber and exposure procedure
The exposure procedure and chamber designed used in
this study is described in more detail in Andersson et al30
and Andersson et al.37 In brief, participants were exposed
to n-butanol (99.4% J.T. Baker) while seated in a windowed
exposure chamber. The exposure chamber had a volume
of 2.7 m3 (height: 200 cm, width: 90 cm, depth: 150 cm)
and the exposure concentration of n-butanol was 11.5 mg/
m3 (3.7 ppm). The odorant n-butanol was chosen for the
exposure procedure based on a pilot test in which MCS suf-
ferers judged the compound to be symptom-eliciting and
because it had been used successfully in previous challenge
studies with MCS participants.37 38 The concentration of
n-butanol was clearly detectable (above the olfactory
threshold 0.012 mg/m3 39), but well below its threshold for
sensory irritation (75 mg/m3 40).
Unknown to the participants, no odorant was deliv-
ered into the exposure chamber during the ﬁrst 10 min
of testing (ﬁgure 1). After this initial period of blank
exposure, n-butanol was released into the chamber and
reached its peak concentration in about 8 min later
(ﬁgure 1). The concentration remained at this peak
level for the rest of the session (42 min). The tempera-
ture and relative humidity inside the chamber were con-
tinuously monitored during the exposures and the
mean temperature was 22°C (±1°C) and the relative
humidity was 16% (±2%), same as the concurrent
humidity outside the chamber.
At baseline and at regular intervals during the exposure
session, the participants rated the perceived intensity and
valence as well as the level of possible symptoms.
Additionally, autonomic recordings of breathing rate,
tonic electrodermal activity, pulse rate and pulse rate vari-
ability were obtained at baseline and periodically during
the exposure. A more detailed description of the method-
ology used for collection of self-reported ratings and auto-
nomic recordings has been published separately in
Andersson et al30 verifying the experimental setup’s cap-
ability to elicit characteristic MCS symptoms in the MCS
group and to produce the anticipated group differences.
Sample collection
Venous blood of 8 mL were collected in anticoagulant
Na2-EDTA tubes (Greiner Bio-One, Kremsmünster,
Austria) at three TPs; within 30 min prior to the exposure
(TP1), within 15 min postexposure (TP2) and 4 hours
after the exposure session had been terminated (TP3)—
outlined in ﬁgure 1. All blood sampling and analyses were
performed by personnel blinded to group afﬁliation.
Blood samples were immediately centrifuged at 1500 g for
10 min without brake and the buffy coat layer was carefully
collected in 1.2 mL RNAlater solution (Life Technologies
RNA stabilisation reagent) according to the manufacturer’s
instructions and stored at −80°C until RNA extraction.
RNA extraction and gene expression analysis
RNA isolation, cDNA synthesis and gene expression ana-
lysis were conducted by SABioscience service core
laboratories (SABioscience/Qiagen, Hilden, Germany),
using the protocols described below.
Figure 1 Overview of the exposure chamber procedure and sampling of blood. During the precondition, participants were
seated in the exposure chamber with the door open. The door was thereafter closed, and the chamber session began at minute
0. During the first 10 min of testing, no odorant was delivered into the chamber, after which n-butanol was released into the
chamber and reached a peak concentration after about 8 min. The concentration remained at this peak level (3.7 ppm) for the
remaining part of the exposure session. Venous blood samples was collected within 30 min prior to the exposure session (TP1),
within 15 min postexposure session (TP2) and again 4 hours after the exposure session was terminated (TP3). TP, time point.
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RNA isolation
RNA was isolated using a modiﬁed RNeasy Micro Kit
protocol (Qiagen, Valencia, California, USA). After
thawing, white blood cells (WBCs) were harvested from
400 μL buffy coat/RNAlater sample by centrifugation for
1 min at 14 000 rpm and the supernatant was subse-
quently discarded. WBCs were lysed by addition of
600 μL RLT buffer (guanidine thiocyanate buffer—
Qiagen, Valencia, California, USA) containing 10 μL
β-mercaptoethanol per 1 mL RLT buffer. After mixing
for 15 s at 50 Hz in a tissue lyser (TissueLyser II—
Qiagen, Valencia, California, USA), 50 μL 3M sodium
acetate, 300 μL acid phenol and 300 μL chloroform were
added, it was again mixed for 1 min at 50 Hz and subse-
quently centrifuged for 5 min at 14 000 rpm. One milli-
litre ethanol and 200 μL AVL buffer (Qiamp viral RNA
mini kit, Qiagen, Valencia, California, USA) were added
to the aqueous phase and mixed. The mixture was trans-
ferred to an RNeasy mini column, applied to vacuum on
a QIAvac station (Qiagen, Valencia, California, USA)
and washed with 350 μL RW1 buffer (included in the
RNeasy Micro Kit—Qiagen, Valencia, California, USA).
Then, 80 μL DNase I was added to the column, and the
column with DNase I solution was incubated for 30 min
at room temperature. Subsequently, the column was
washed once with 350 μL buffer RW1, two times with
700 μL buffer RPE and ﬁnally with 700 μL 80% ethanol.
After drying the membrane, the column was transferred
to a collection tube and RNA was eluted with 30 μL
RNase-free water by centrifugation for 1 min at
10 000 rpm. RNA concentration and quality for each
sample were determined as OD260/280 using a nano-
drop spectrophotometer and for the integrity measure-
ment, 1 μL of the total RNA was analysed on an RNA
6000 nanochip using an Agilent Bioanalyzer. Total RNA
concentrations were in the range of 14–231 μg/uL and
the RNA integrity number was above 7.5 for all samples.
cDNA synthesis
cDNA was synthesised from 1.0 μg total RNA in a 20 μL
reaction using QIAGEN RT² First Strand Kit (catalog
number 330401) designed and optimised gene expres-
sion analysis with QIAGEN RT² Proﬁler PCR Arrays and
RT² qPCR Primer Assays.
Gene selection
Genes included in the study either play a role in regula-
tion of the common symptoms of MCS or in the physio-
logical response observed during the exposure session, or
they are involved in the proposed biological explanatory
models of MCS. Additionally, as the non-speciﬁc symp-
toms in MCS somewhat resemble other unexplained dis-
orders (eg, ﬁbromyalgia and chronic fatigue syndrome),
research ﬁndings into these disorders have been used as
inspiration in selection of genes based on the possibility
of a shared or overlapping pathophysiology.19 24 41 42 All
genes quantiﬁed are listed in table 1 with genes grouped
into the biochemical pathways they are associated with,
that is, immune regulation, sensory ion channel recep-
tors, serotonin and receptors for neuromodulators,
neural growth factor, the antioxidative enzyme, catalase,
and the sphingosine-1-phosphate pathway. A short
description of the motivation behind inclusion of each
gene and reference to the relevant scientiﬁc literature is
provided in online supplementary ﬁle 1.
RT2 Profiler PCR array
Each 384-well (32 genes/12 samples) array contained 26
target genes, one reverse transcription control (NRT),
one template control (NTC) and one positive PCR con-
trols (PPC) as well as the following housekeeping
genes (HKG); 18S ribosomal RNA (18SrRNA—Refseq#
X03205.1), ribosomal protein, large, P0 (RPLP0—Refseq#
NM_001002), hydroxymethylbilane synthase (HMBS—
Refseq# NM_000190). Three hundred and eighty-four-well
Custom RT2 Proﬁler PCR Arrays were performed accord-
ing to the manufacturer’s instructions (Qiagen, Valencia,
California, USA) using the ABI prism 7900 HT (384-well
format) instrument (Applied Biosystems, Foster City,
California, USA) and ABI Prism 7900 SDS software V.2.1.
Using a robotic work station, cDNA templates were mixed
with ready-to-use RT2 qPCR Master Mixes and 10 μL of
the PCR component mix was aliquoted into each well
containing predispensed gene-speciﬁc primer sets. Each
plate was loaded with cDNA from 12 individual partici-
pants and all cDNA samples were run in duplicate on dif-
ferent arrays. Gene expression measured from each
participant was normalised according to the average
expression level of RPLP0 and HMBS in the same partici-
pant. The speciﬁcity of the SYBR Green assay was con-
ﬁrmed by melting point analysis.
Statistical analysis
The gene expression amounts were computed relative to
HKG using the delta cycle threshold (dCT) method.
The 2^-Δct values for all participants in each group were
combined into a MCS or control group expression value
that was used for group comparisons. Data are presented
as group mean±SD and analysed using either Student’s
t-test or one-way analysis of variance with p<0.05 consid-
ered to be statistically signiﬁcant for each comparison. p
Values were subsequently adjusted for multiple testing
by the Holm-Bonferroni method.43 In addition to the
three TP comparisons, TP measures were also combined
into a single area under the curve (AUC) value. For all
candidate genes, AUC for each participant was com-
puted by summing 2^-Δct values at TP1, TP2 and TP3 by
trapezoidal integration and these values were then com-
bined intro mean group AUC values. For statistical ana-
lysis, group 2^-Δct values and group AUC values were
log-transformed. Principal component analysis (PCA)
was performed on autoscaled 2^-Δct values at TP1, TP2
and TP3 as well as on the AUC for expression of each
gene during the exposure using the software package
Latentix V.2.12 (http://www.latentix.com), and scores
for principal component (PC)1, PC2 and PC3 were
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plotted against each other to detect the otherwise
hidden patterns in the data set.
Software
Excel was used to calculate the relative mRNA levels and
calculate AUC values. Excel and Graphad Prims were
used to create table and graphs, and multivariate PCA
was performed using LatentiX V.2.11 (Latent5; http://
www. latentix.com)
RESULTS
Participant characteristics
A total of 36 participants participated in the study; 18 ful-
ﬁlling the criteria for MCS and 18 enrolled as healthy
controls. Blood samples from one control participant
were lost during the RNA extraction procedure, leaving a
control group of 17 participants. Selected characteristics
of both study groups are shown in table 2. More women
than men participated in the study and the mean age was
comparable between the two groups. Compared with the
controls, the MCS group showed a signiﬁcantly higher
score on the Chemical Sensitivity Scale36 (p<0.001). A
more comprehensive characterisation of the study popu-
lation can be found in Andersson et al,30 showing a signiﬁ-
cantly higher score on the somatisation subscale of the
Table 1 Genes selected for quantitative expression analysis
Class Gene name Acronym Refseq #
Primer catalog
number*
Immune regulation Interleukin-1β IL-1β NM_000576 PPH00171C
Interleukin-2 IL-2 NM_000586 PPH00172C
Interleukin-6 IL-6 NM_000600 PPH00560C
Interleukin-8 IL-8 NM_000584 PPH00568A
Interleukin-10 IL-10 NM_000572 PPH00572C
Tumour necrosis factor-α TNF-α NM_000594 PPH00341F
Nitric oxide synthase 2, inducible NOS2 NM_000625 PPH00173F
Nuclear factor of κ light polypeptide gene
enhancer in B cells 1
NFKB1 NM_003998 PPH00204F
Sensory ion channels Purinergic receptor P2X, ligand-gated ion
channel, 4
P2RX4 NM_002560 PPH00341F
Purinergic receptor P2X, ligand-gated ion
channel, 5
P2RX5 NM_175081 PPH19418A
Transient receptor potential cation channel,
subfamily V, member 1
TRPV1 NM_018727 PPH08086F
Transient receptor potential cation channel,
subfamily V, member 4
TRPV4 NM_021625 PPH16107B
Transient receptor potential cation channel,
subfamily A, member 1
TRPA1 NM_007332 PPH12389E
Glutamate receptor, ionotropic, kainate 2 GRIK2 NM_021956 PPH01863A
Glutamate receptor, ionotropic, N-methyl
D-aspartate 1
GRIN1 NM_007327 PPH01823F
Serotonin receptor 5-hydroxytryptamine (serotonin) receptor 1A HTR1A NM_000524 PPH02530E
5-hydroxytryptamine (serotonin) receptor 2A HTR2A NM_000621 PPH01861G
Adrenergic receptors Adrenergic β-1 receptor ADRB1 NM_000684 PPH02091B
Adrenergic β-2 receptor ADRB2 NM_000024 PPH01856E
Catechol-O-methyltransferase COMT NM_000754 PPH01584B
Substance P receptor Tachykinin receptor 1 TACR1 NM_001058 PPH01825A
Nerve growth factor Brain-derived neurotrophic factor BDNF NM_001709 PPH00569F
Antioxidative enzyme Catalase CAT NM_001752 PPH00420B
Sphingosine-1-phosphate
pathway
N-acylsphingosine amidohydrolase (acid
ceramidase) 1
ASAH1 NM_004315 PPH02492F
Sphingosine kinase 1 SPHK1 NM_021972 PPH02491A
Sphingosine-1-phosphate lyase 1 SGPL1 NM_003901 PPH13925A
*Qiagen catalogue number for primers optimised and validated for human RT² qPCR Primer Assay (Qiagen, Valencia, California, USA).
Table 2 Observed characteristics of MCS and the control
group
MCS group
(n=18)
Control
group
(n=17) p Value*
Sex male/female, n 2/16 4/13
Age mean (±SD) 44 (14) 40 (14) 0.447
Chemical Sensitivity
Scale mean (±SD)
96 (16) 72 (11) <0.001
*p Values refer to results of Mann-Whitney U test.
MCS, multiple chemical sensitivity.
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symptom checklist (SCL) 90 (p<0.05) associated with MCS,
and with no group differences for depression, anxiety and
perceived stress. Likewise, the MCS group also reported
higher number of morbidities other than MCS. No other
signiﬁcant demographic group differences were found.
Gene expression levels
Expression levels of multiple genes showed only limited
transcriptional activity in leucocytes with cycle threshold
(Ct) values above the predeﬁned cut-off at 35. In order
to secure reliable expression data for the subsequent
analysis, genes with average Ct value equal to or above
34 were excluded from the analysis. This was the case
for the following genes; interleukin (IL)-2, glutamate
receptor, ionotropic, kainate 2, glutamate receptor, iono-
tropic, N-methyl D-aspartate 1, adrenergic β-1 receptor,
5-hydroxytryptamine (serotonin) receptor 1A (HTR1A),
HTR2A, nitric oxide synthase 2, tachykinin receptor 1
and brain-derived neurotrophic factor (see table 1 for
additional gene information).
Baseline gene expression levels
No statistically signiﬁcant group differences in gene
expression were identiﬁed at baseline (TP1) for any of
the 17 genes that were successfully quantiﬁed (ﬁgure 2).
Likewise, PCA of the gene expression patterns revealed
no differences between MCS participants and controls
(data not shown).
Gene expression time course
MCS participantsperceived the n-butanol exposure as
being more intense, more unpleasant and rated symp-
toms to be of greater magnitude compared with controls
as reported in Andersson et al.30 Here, we examined
whether the group differences in symptom elicitation
after the n-butanol exposure were associated with in situ
changes in expression rate of the target genes listed in
table 1. Relative gene expression was monitored at three
TPs and time-course graphs visualising mean expression
levels of target genes IL-1β, IL-6, IL-10, nuclear factor of
κ light polypeptide gene enhancer in B cells, transient
receptor potential cation channel, subfamily V, member
1 (TRPV1), TRPV4, catechol-O-methyltransferase
(COMT) and N-acylsphingosine amidohydrolase (acid
ceramidase) 1 (ASAH1) are depicted in ﬁgure 3.
Time-course graphs of the remaining nine target genes
can be found in the online supplementary ﬁle 2.
The comparable gene expression levels between the
groups measured at baseline allowed for a direct com-
parison of gene expression levels between MCS partici-
pants and controls at TP2 and TP3, without prior
adjustment. However, although visual inspection of
several graphs indicates changes in gene transcription
from TP1 to TP2 and/or TP3 for genes such as IL-10
and TRPV4, the differences were not statistically signiﬁ-
cant. Additionally, repeated blood sampling at three con-
secutive TPs allowed for analyses of time-dependent
changes in gene expression levels taking place simultan-
eously in both groups as a result of the exposure. Yet, no
statistically signiﬁcant time-dependent changes in gene
expression levels were found. A multivariate PCA was
used to explore if the gene expression pattern differed
in MCS participants compared with controls. However,
the analysis did not reveal any statistically signiﬁcant dif-
ferences in score value at PC1, PC2 or PC3, between the
two groups (data not shown).
Figure 2 Ratios of relative gene expression in unexposed MCS versus healthy controls. Data represent ratios of mean with
95% CIs between gene expression levels in leucocytes from MCS participants and healthy controls. Full form of genes
abbreviations are provided in table 1. ADRB2, adrenergic β-2 receptor; ASAH1, N-acylsphingosine amidohydrolase (acid
ceramidase) 1; CAT, catalase; COMT, catechol-O-methyltransferase; IL, interleukin; MCS, multiple chemical sensitivity; NFKB1,
nuclear factor of κ light polypeptide gene enhancer in B cells 1; P2RX4, purinergic receptor P2X, ligand-gated ion channel, 4;
P2RX5, purinergic receptor P2X, ligand-gated ion channel, 5; SGPL1, sphingosine-1-phosphate lyase 1; TNF, tumour necrosis
factor; TRPA1, transient receptor potential cation channel, subfamily A, member 1; TRPV1, transient receptor potential cation
channel, subfamily V, member 1; TRPV4, transient receptor potential cation channel, subfamily V, member 4.
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Figure 3 n-Butanol exposure and relative gene expression levels. Data are shown as mean levels with SD of IL-1β, IL-6, IL-10,
NFKB, TRPV1, TRPV4, COMT and ASAH1 quantified in buffy coat samples from the MCS participants and control. Data is
presented at each of the three TPs of sampling: within 30 min prior to the exposure (TP1), within 15 min postexposure (TP2) and
4 hours after the exposure session had been terminated (TP3). ASAH1, N-acylsphingosine amidohydrolase (acid ceramidase) 1;
COMT, catechol-O-methyltransferase; IL, interleukin; MCS, multiple chemical sensitivity; NFKB1, nuclear factor of κ light
polypeptide gene enhancer in B cells 1; TP, time point; TRPV1, transient receptor potential cation channel, subfamily V, member
1; TRPV4, transient receptor potential cation channel, subfamily V, member 4.
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AUC comparison
After adjusting for multiple comparisons, we identiﬁed
no signiﬁcant AUC differences between MCS partici-
pants and controls. Based on single comparisons of
gene expression, we did observe an increased AUC value
for IL-6 in the MCS group (unadjusted p=0.03), as well
as a tendency towards increased AUC in the MCS group
for IL-10 (p=0.074) and ASAH1 (p=0.092; table 3).
Generally, the AUC estimates revealed higher expression
rates in the MCS group compared with controls,
although not signiﬁcant (table 3). Moreover, using PCA
to explore the multivariate expression pattern of all suc-
cessfully analysed genes did not reveal any statistical dif-
ferences between the groups in the score values in
either PC1, PC2 or PC3, nor in the three-dimensional
space when the PCs were plotted against each other.
PC1 explained the ∼40% variation in the data set, PC2
∼15% and PC3 ∼11%, see online supplementary ﬁle 3.
DISCUSSION
This exploratory study used gene expression quantiﬁca-
tion for the ﬁrst time to identify gene transcriptional
changes in MCS participants upon a symptom eliciting
n-butanol exposure session, when compared with con-
trols.30 Overall our data demonstrated no statistically sig-
niﬁcant abnormalities in gene expression regulation in
MCS participants at any of the three TPs. Nevertheless,
exploration of the longitudinal responses to the expos-
ure session represented by an integrated AUC value did
reveal a tendency towards an overall increase in tran-
scription rate associated with MCS, most notable for IL-6
(unadjusted p=0.03). As depicted in table 2, more
women than men participated in the study with a mean
age in the 40s, which is in accordance with earlier
reported characteristics of participants with MCS,23 44
and the Chemical Sensitivity Scale score was higher for
the MCS group, indicating that the case criteria for
inclusion were successful.
However, how to deﬁne and segregate MCS partici-
pants from healthy controls is a recurrent challenge in
the ﬁeld of MCS and many studies rely entirely on sub-
jective information provided by the affected participants
or clinicians.45 In this study, we conﬁrmed the presence
of a MCS phenotype using questionnaire data (ie,
Chemical Sensitivity Scale, table 2) as well as objective
physiological and subjective psychological measures col-
lected during the exposure session, as depicted by
Andersson et al.30 The phenotypic response observed
showed that over the course of the exposure session, the
MCS group perceived the odour intensities of n-butanol
as more intense and more unpleasant, and they
reported more symptoms. Additionally, higher than
normal pulse rate and lower than normal pulse rate vari-
ability were associated with the MCS group.30 Overall,
the discrepancies between MCS participants and
Table 3 AUC values for each gene
MCS group Control group
Genes Mean AUC ±SD Mean AUC ±SD p Values* Adjusted p values†
IL-1β 1.352 0.705 1.050 0.649 0.235 1.0
IL-6 0.018 0.009 0.012 0.006 0.030 0.45
IL-8 1.133 0.687 1.316 0.671 0.343 1.0
IL-10 0.025 0.036 0.009 0.004 0.074 1.0
TNFα 0.302 0.189 0.260 0.085 0.494 1.0
NFKB1 0.865 0.321 0.714 0.160 0.105 1.0
P2RX4 0.455 0.217 0.374 0.104 0.206 1.0
P2RX5 0.597 0.217 0.584 0.290 0.794 1.0
TRPV1 0.102 0.031 0.095 0.036 0.593 1.0
TRPV4 0.016 0.019 0.008 0.005 0.129 1.0
TRPA1 0.010 0.006 0.008 0.005 0.385 1.0
ADRB2 1.022 0.332 1.006 0.330 0.781 1.0
COMT 0.369 0.181 0.311 0.079 0.259 1.0
CAT 6.314 2.154 6.527 2.619 0.900 1.0
ASAH1 11.904 4.297 9.657 2.561 0.092 1.0
SPHK1 0.101 0.066 0.080 0.030 0.269 1.0
SGPL1 0.598 0.171 0.544 0.136 0.350 1.0
*p Values calculated for each gene using Student’s t-test.
†pValues after Holm-Bonferroni correction for multiple testing.
Values have been estimated using trapezoidal integration covering the 5-hour time span between initial and the last blood sample. AUC
values are presented as group means with SD.
ADRB2, adrenergic β-2 receptor; ASAH1, N-acylsphingosine amidohydrolase (acid ceramidase) 1; AUC, area under the curve; CAT, catalase;
COMT, catechol-O-methyltransferase; IL, interleukin; MCS, multiple chemical sensitivity; NFKB1, nuclear factor of κ light polypeptide gene
enhancer in B cells 1; P2RX4, purinergic receptor P2X, ligand-gated ion channel, 4; P2RX5, purinergic receptor P2X, ligand-gated ion
channel, 5; SGPL1, sphingosine-1-phosphate lyase 1; SPHK1, sphingosine kinase 1; TNF, tumour necrosis factor; TRPA1, transient receptor
potential cation channel, subfamily A, member 1; TRPV1, transient receptor potential cation channel, subfamily V, member 1; TRPV4,
transient receptor potential cation channel, subfamily V, member 4.
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controls on the parameters presented above suggest that
the case criteria for inclusion in the study were success-
ful, which underpin the rationality of gene expression
comparisons presented here. Nevertheless, although
MCS participants were selected using common MCS cri-
teria and the controls group is age and gender matched,
unaccounted factors such as overall health status, life-
style, socioeconomic status and personality traits among
participants do have the potential to affect individual
participant’s gene expression levels and thereby the
overall ﬁndings of the study.40 Consequently, when
working with a poorly deﬁned syndrome such as MCS,
any study conclusions would beneﬁt from being
repeated in a larger case–control setup or even in a
population-based study design.
Our ﬁrst hypothesis was that symptom-free participants
with MCS would have similar gene expression levels at
baseline compared with age-matched and sex-matched
healthy control group. This hypothesis was supported by
the current results, as no signiﬁcant group differences
were observed at baseline (ﬁgure 2). The baseline
measure is also in accordance with the ﬁnding described
in Andersson et al,30 who found that prior to the expos-
ure session while being seated inside the exposure
chamber with the door open, ratings of symptoms and
chemosensory perception were comparable between
MCS participants and controls. Combined, these results
suggest that MCS participants do not differ from con-
trols during unexposed conditions in terms of transcript
rates of the genes included. Therefore, any subsequent
group-associated changes in gene expression can be
attributed to the exposure session.
Our second hypothesis was that upon an n-butanol
exposure session MCS participants and healthy controls
would show differential gene-expression patterns. This
was only moderately substantiated as our result did not
demonstrate any abnormal gene regulation in WBC
from MCS participants immediately after exposure
(TP2), 4 hours later (TP3) or accumulated over the
5-hour time course. However, IL-6, IL-10 and ASAH1 did
show a trend towards overall higher expression levels in
MCS participants over the 5-hour time course (table 3).
For IL-10, and to some degree TRPV4 and COMT,
expression rates did rise at TP2 immediately after expos-
ure (although not reaching signiﬁcance) in the MCS
group and subsequently declined indicative of transcrip-
tional activation of those genes in response to the expos-
ure paralleled with symptoms elicitation. Similar but
more apparent ﬁndings have been observed in gene
expression studies encompassing patients with chronic
fatigue syndrome.27 28
Two overall observations were made that may have had
pivotal inﬂuence on the study outcome. First, although
group differences were not signiﬁcant, the mean tran-
scription rates were higher in the MCS group for all
genes, except for IL-8 and catalase (ﬁgures 1 and 2,
table 3 and see online supplementary ﬁle 2). Second,
the intragroup variation was noticeably greater among
MCS participants than controls for all comparisons, even
at baseline (ﬁgures 1 and 2, table 3 and see online
supplementary ﬁle 2). The current data do not provide
any deﬁnitive explanation for these observations.
However, as depicted in Andersson et al,30 the MCS
group reported greater symptoms and rated the expos-
ure session as more intense during the initial 10 min of
blank exposure compared with controls. It was put
forward that this MCS associated reaction to blank
exposure was likely the result of increased expectancies,
that is, MCS participants were aware that the exposure
session was intended to induce symptom elicitation.
Although speculative, negative expectancies may likewise
have inﬂuenced gene expression levels among MCS par-
ticipants from even prior to the exposure session,
leading to nervous behaviour and increased stress levels.
The magnitude of stress introduced and how the stress
inﬂuences gene expression would also differ consider-
able among the exposed participants based on personal-
ity characteristics, which can explain, at least partially,
the pronounced heterogeneity observed within the MCS
group.
As emphasised earlier, future studies applying gene
expression proﬁling in MCS research would beneﬁt
from either a more homogeneous study population,
although such a study would only represent a fraction of
the MCS community, or a higher number of partici-
pants, thereby providing a more representative platform
for the analysis as well as increasing the statistical power.
A large study population would also make subgroup ana-
lysis possible, taking into account the intragroup differ-
ences. Similarly, the inclusion of additional genes, for
example, more immunological mediators, may have
strengthened the study by providing a more comprehen-
sive expressional characterisation. However, this was an
exploratory study, and our results do suggest that gene
expression characterisation of MCS participants on
group levels is challenging. The genetic as well as epi-
genetic heterogeneity between MCS participants has
been highlighted before,20 46 and it has been recom-
mended to divide MCS participants into subgroups of
individuals stratiﬁed according to the symptom patterns
or exposure agent reactivity.46 47 This strategy was not
considered applicable with data from 18 individuals con-
stituting the MCS group, as dividing participants into
even smaller subgroups would have lowered the statis-
tical power even further. Unfortunately, 36 participants
was the maximum number of participants that systemat-
ically could be recruited, fulﬁlling the criteria, and com-
pleting the exposure procedure within the time and
resources available. It could also have strengthened the
study if a blank exposure sample in a blinded setup was
included. Unfortunately, blood sample collection during
the initial 10 min of blank exposure was not possible
due to the design of the exposure chamber.
There exists a general consensus among clinicians and
researchers that neurophysiological abnormalities play a
vital role in MCS pathogenesis and both the neural and
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central sensitisation theories have been proposed as the
driving mechanism in MCS.15 24 41 48 49 In light of the
recent years advances made using electrophysiological
outcome measures to analyse CNS activation/deactiva-
tion patterns among MCS participants during olfactory
stimulation, it could be highly beneﬁcial for future
studies of gene expression in MCS upon symptoms elicit-
ation to combine the current experimental setup with
one of those technologies. Brain imaging technologies
such as positron emission tomography, functional MRI
and near-infrared spectroscopy have been used in a
number of studies to detect altered reactions in the CNS
of MCS participants upon olfactory stimulation.50–55 By
combining physiological phenotype measured during
exposure,30 with brain imaging during the exposure and
WBC gene expression analysed in a multifaceted ana-
lysis, a more comprehensive model could be designed in
an attempt to describe the underlying pathogenesis.
CONCLUSION
Collectively, our study did not reveal any statistically sup-
ported gene regulatory changes in MCS participants upon
a symptom-eliciting exposure session using a low dose of
the odorant n-butanol. MCS participants could therefore
not be separated from controls based on gene expression
analysed and we identiﬁed no correlation between regula-
tion of speciﬁc genes and symptoms elicitation.
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